ML 218 hydrochloride
Cat. No. 4507
Chemical Name: 3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3
Biological ActivitySelective inhibitor of T-type calcium channels (IC50 values are 270 and 310 nM for Cav3.3 and Cav3.2 respectively in a patch EP assay). Decreases burst activity in STN neurons; reduces cataleptic behaviour in an in vivo rat model of Parkinson's disease. Displays no significant inhibition of L- or N-type calcium channels, Kir6 (KATP) or KV11.1 (hERG) potassium channels. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Galvan et al (2016) Lack of antiparkinsonian effects of systemic injections of the specific T-type calcium channel blocker ML218 in MPTP-treated monkeys. ACS Chem.Neurosci. PMID: 27596273 .
Xiang et al (2011) The discovery and characterization of ML218: A novel, centrally active T-type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease. ACS Chem.Neurosci. 2 730. PMID: 22368764.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for ML 218 hydrochloride include:
Galvan et al (2016) Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys ACS ChemicalNeuroscience. PMID: 27596273.
Do you know of a great paper that uses ML 218 hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: ML 218 hydrochloride, supplier, ML218, HCl, CID45115620, T-type, calcium, channels, CAV3.1, CAV3.2, CAV3.3, inhibitors, inhibits, selective, Tocris Bioscience, Voltage-gated Calcium Channel (CaV) Blocker products
Find multiple products by catalog number
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands